PharmaJet to Highlight Benefits of Needle-free Intradermal Delivery at Medical Conference in Ethiopia
GOLDEN, Colo.--(BUSINESS WIRE)--Feb 19, 2025--
PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that they will share the latest routine immunization study results at the 61 st Annual Medical Conference and International Health Exhibition to be held on February 21-22, 2025 at the Haile Grand in Addis Ababa, Ethiopia. The presentation, entitled Intradermal needle-free vaccine delivery to reduce Ethiopia's immunization costs and improve coverage, will be presented by Paul LaBarre, Vice President Global Business Development, PharmaJet. This event will bring together physicians from across the nation, along with representatives from Ethiopian Medical Association chapter offices, medical specialty societies, medical schools, the Ministries of Health (MoH) and Education, sister health professional associations, and partners.
This press release features multimedia. View the full release here:
Child receives polio immunization with the PharmaJet Tropis Needle-free Injection System as part of a recent campaign in Nigeria. (Photo: Business Wire)
Intradermal (ID) vaccine administration can enable new vaccine strategies that leverage improved cross-protection, duration of immune response, and mucosal immunity. However, administration to the ID space has been difficult using traditional needle and syringe. Needle-free administration using the PharmaJet Tropis ® ID System facilitates ID delivery with improved acceptability and speed of administration. Tropis, which has been used to administer polio vaccinations to more than 10 million children, is the first and only needle-free ID delivery technology to achieve WHO prequalification.
A recent randomized controlled implementation study in Nigeria 1 evaluated the impact on coverage, costs, and acceptability of intradermal fractional inactivated poliovirus vaccine (fIPV) administration using the Tropis compared to the standard of care (SoC - full-dose, IPV intramuscular delivery with needle and syringe). The study demonstrated:
Increased coverage: Among those vaccinated with Tropis, IPV2 coverage was 11.2% higher compared to the SoC.
Decreased total immunization costs: Incremental savings with needle-free could range from $0.07 to $1.00 per dose administered across evaluated scenarios with up to 47% total immunization cost savings compared to SoC at full scale.
High acceptability: 94% caregivers reported high acceptability of Tropis. Healthcare worker preference for Tropis over the SoC was 95%. Tropis reduced administration time by five seconds on average compared to the SoC.
'The Nigeria study results demonstrate how using Tropis for routine immunization programs can provide significant benefits at all levels of the healthcare system,' said Paul LaBarre, Vice President of Global Business Development, PharmaJet. 'Leveraging recent evidence from Tropis use in campaigns and routine immunization in Pakistan, 2 Somalia, 3 and Nigeria, 4 we look forward to working with the Ethiopian Ministry of Health and other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs.'
For more information visit the PharmaJet booth at the exhibition room or go to the PharmaJet website https://pharmajet.com.
About PharmaJet
The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, and allow for a preferred patient and caregiver experience, while also being safe, fast, and easy-to-use. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit https://pharmajet.com or contact PharmaJet here.
[email protected]
1-888-900-4321 Option 3
SOURCE: PharmaJet
Copyright Business Wire 2025.
PUB: 02/19/2025 03:10 AM/DISC: 02/19/2025 03:10 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination
EWING, N.J., June 6, 2025 /PRNewswire/ -- Church & Dwight Co., Inc. is voluntarily recalling all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. The products are being recalled due to potential microbial contamination identified as fungi in cotton swab components. Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions. To date, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico. Recalled Product Information Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What Consumers Should Do Consumers who have purchased any of the recalled products should stop using the product immediately. Please visit or call its Consumer Relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its Consumer Relations team Monday through Friday, 9am – 5pm ET. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall. About Church & Dwight Co., Inc. Church & Dwight Co., Inc. is a leading manufacturer of consumer household and personal care products. For more information, visit Media Contact:Keith View original content to download multimedia: SOURCE Church & Dwight Co. Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination
EWING, N.J., June 6, 2025 /PRNewswire/ -- Church & Dwight Co., Inc. is voluntarily recalling all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. The products are being recalled due to potential microbial contamination identified as fungi in cotton swab components. Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions. To date, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico. Recalled Product Information Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What Consumers Should Do Consumers who have purchased any of the recalled products should stop using the product immediately. Please visit or call its Consumer Relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its Consumer Relations team Monday through Friday, 9am – 5pm ET. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall. About Church & Dwight Co., Inc. Church & Dwight Co., Inc. is a leading manufacturer of consumer household and personal care products. For more information, visit Media Contact:Keith View original content to download multimedia: SOURCE Church & Dwight Co. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
